LA
JOLLA, Calif., Oct. 16,
2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica")
(Nasdaq: CALC), a clinical-stage biopharmaceutical company focused
on developing novel calcium release-activated calcium (CRAC)
channel inhibition therapies for acute and chronic inflammatory and
immunologic illnesses, today announced the acceptance of a
late-breaking abstract for a plenary presentation by Prof.
Robert Sutton from the University of Liverpool and Liverpool University Hospitals NHS Foundation Trust
at the upcoming American College of Gastroenterology (ACG) 2024
Annual Scientific Meeting being held October
28-30 in Philadelphia, PA
and virtually. Prof. Sutton is the chair of the Steering Committee
for the CARPO acute pancreatitis (AP) with accompanying systemic
inflammatory response syndrome (SIRS) clinical trial.
Details for the presentation are as follows:
Presenter: Prof. Robert
Sutton, B.A. (Hons), M.B., B.S., D.Phil., FRCS, University of Liverpool and Liverpool University Hospitals NHS Foundation
Trust
Session Title: Simultaneous Plenary Session 4A
Session Date and Time: Wednesday,
October 30, 10:00-10:15 a.m.
ET
Location: Grand Ballroom
Abstract #: 64
Abstract Authors: Prof. Robert
Sutton, B.A. (Hons), M.B., B.S., D.Phil., FRCS, Liverpool
Pancreatitis Research Group, Institute of Systems, Molecular and
Integrative Biology, University of
Liverpool and Liverpool
University Hospitals NHS Foundation Trust; Pramod K. Garg, M.D., D.M., Department of
Gastroenterology, All India Institute of Medical Sciences; Bechien
Wu, M.D., MPH, Division of Gastroenterology, Kaiser Permanente Los
Angeles Medical Center; Sudarshan
Hebbar, M.D., CalciMedica, Inc.; W. Frank Peacock, M.D., FACEP, FACC, FESC,
Department of Emergency Medicine, Baylor
College of Medicine; Timothy B.
Gardner, M.D., M.S., FACG, Section of Gastroenterology and
Hepatology, Department of Medicine, Dartmouth-Hitchcock Health
About CalciMedica
CalciMedica is a clinical-stage
biopharmaceutical company focused on developing novel CRAC channel
inhibition therapies for inflammatory and immunologic
diseases. CalciMedica's proprietary technology targets
the inhibition of CRAC channels to modulate the immune response and
protect against tissue cell injury, with the potential to provide
therapeutic benefits in life-threatening inflammatory and
immunologic diseases for which there are currently no approved
therapies. CalciMedica's lead product candidate Auxora™
has demonstrated positive and consistent clinical results in
multiple completed efficacy clinical trials. CalciMedica has
announced topline data for a Phase 2b
trial (called CARPO – NCT04681066) in patients with AP with
SIRS and completed a Phase 2 trial (called CARDEA
– NCT04345614) in patients with COVID pneumonia. The Company
is currently conducting a Phase 2 trial (called KOURAGE
– NCT06374797) in patients with AKI with associated AHRF with
data expected in 2025 and continuing to support the ongoing Phase
1/2 trial (called CRSPA – NCT04195347) in patients with AIPT
with data expected in 2025. CalciMedica was founded by
scientists from Torrey Pines Therapeutics and the Harvard CBR
Institute for Biomedical Research, and is headquartered in La
Jolla, CA. For more information, please
visit www.calcimedica.com.
Forward-Looking Statements
This communication contains
forward-looking statements which include, but are not limited to,
CalciMedica's ongoing and planned clinical trials and the timing,
design, expected patient enrollment thereof and the expected timing
for the release of data from those trials, including its Phase
2b CARPO trial of Auxora for AP with
accompanying SIRS, its ongoing Phase 1/2 CRSPA trial of Auxora in
pediatric patients with AIPT, and its planned Phase 2 KOURAGE trial
of Auxora in AKI with associated AHRF; the potential benefits of
Auxora for the treatment of AP, AKI and AIPT; and the potential of
CalciMedica's proprietary technology to provide therapeutic
benefits in life-threatening inflammatory and immunologic diseases.
These forward-looking statements are subject to the safe harbor
provisions under the Private Securities Litigation Reform Act of
1995. CalciMedica's expectations and beliefs regarding these
matters may not materialize. Actual outcomes and results may differ
materially from those contemplated by these forward-looking
statements as a result of uncertainties, risks, and changes in
circumstances. Risks and uncertainties that could cause actual
outcomes and results to differ materially from those contemplated
by the forward-looking statements are included under the caption
"Risk Factors" in CalciMedica's Annual Report on Form 10-K for
the year ended December 31, 2023, and
elsewhere in CalciMedica's subsequent reports on Form 10-K, Form
10-Q or Form 8-K filed with the SEC from time to time and available
at www.sec.gov. These documents can be accessed on CalciMedica's
web page at ir.calcimedica.com/financials-filings/sec-filings. The
forward-looking statements contained herein are made as of the date
hereof, and CalciMedica undertakes no obligation to update them
after this date, except as required by law.
CalciMedica Contact:
Investors and Media
Argot Partners
Sarah Sutton/Kevin Murphy
calcimedica@argotpartners.com
(212) 600-1902
View original content to download
multimedia:https://www.prnewswire.com/news-releases/calcimedica-announces-upcoming-late-breaker-plenary-presentation-at-the-american-college-of-gastroenterology-acg-2024-annual-scientific-meeting-302277217.html
SOURCE CalciMedica, Inc.
